Ethical, legal and social implications of genetically modified organism in the shadow of advanced genetic tools

In order to define the term GMO, different scientific definitions and legal explanations are available. In the regulation process of GM foods, the US and EU legal frameworks are based on the methodologies themselves. Currently, for the production of GMOs, several genome editing tools are available. Along with different site-directed nucleases (ZFN, TALENs, etc.), RNAi and CRISPR/Cas9 have proven to be the very effective tools for genome editing. According to the current EU legislative, introduced in 2018, CRISPR/Cas9 and RNAi techniques are regulated as methods that produce GMOs, because the methodology of the process itself resembles the traditional breeding methods. In the past few years, a large number of scientific publications have confirmed that CRISPR/Cas9 and RNAi technology produce GMOs, supporting and suggesting that the legislation policies in the EU and especially in the USA have to be elaborated. Besides, a huge public pressure makes it difficult to develop and implement new methodologies for GMO production. For this reason, ELSI society is responsible to investigate and question whether the new genetic engineering techniques produce GMO food that is safe for human consumption

The Gut-Brain Axis in Foetal-Maternal Relationship

Gut-brain axis (GBA) represents a bidirectional communication between the central nervous system (CNS) and gastrointestinal (GI) tract. Microbiota found in GI tract has beneficial relationship with their host and can affect the brain, behavior. Studies performed on animals suggest that any change in the composition of microbiota might cause alternations in behavior. In the same way, changes in behavior such as stress, showed to affect the microbiota. Moreover, the composition of the maternal microbiome in pregnancy is known to adversely influence neonatal and infant health and preterm birth. Mother’s microbiome is inherited from the mother to children

Perceptions of students in health and molecular life sciences regarding pharmacogenomics and personalized medicine

Abstract Background Increasing evidence is demonstrating that a patient’s unique genetic profile can be used to detect the disease’s onset, prevent its progression, and optimize its treatment. This led to the increased global efforts to implement personalized medicine (PM) and pharmacogenomics (PG) in clinical practice. Here we investigated the perceptions of students from different universities in Bosnia and Herzegovina (BH) towards PG/PM as well as related ethical, legal, and social implications (ELSI). This descriptive, cross-sectional study is based on the survey of 559 students from the Faculties of Medicine, Pharmacy, Health Studies, Genetics, and Bioengineering and other study programs. Results Our results showed that 50% of students heard about personal genome testing companies and 69% consider having a genetic test done. A majority of students (57%) agreed that PM represents a promising healthcare model, and 40% of students agreed that their study program is well designed for understanding PG/PM. This latter opinion seems to be particularly influenced by the field of study (7.23, CI 1.99–26.2, p = 0.003). Students with this opinion are also more willing to continue their postgraduate education in the PM (OR = 4.68, CI 2.59–8.47, p < 0.001). Furthermore, 45% of students are aware of different ethical aspects of genetic testing, with most of them (46%) being concerned about the patient’s privacy. Conclusions Our results indicate a positive attitude of biomedical students in Bosnia and Herzegovina towards genetic testing and personalized medicine. Importantly, our results emphasize the key importance of pharmacogenomic education for more efficient translation of precision medicine into clinical practice

Association of IRS1 genetic variants with glucose control and insulin resistance in type 2 diabetic patients from Bosnia and Herzegovina

Previous studies reported conflicting results regarding association of insulin receptor substrate 1 (IRS1) gene variation with type 2 diabetes (T2D) and insulin resistance (IR) in different ethnic groups. We examined the association of rs7578326, rs2943641, and rs4675095 in the IRS1 gene with T2D and related traits in a population from Bosnia and Herzegovina, which is one of the European countries with the highest T2D prevalence of 12.5%. Our study included 390 T2D patients and 252 control subjects. Biochemical parameters, including fasting glucose (FG), fasting insulin (FI), homeostasis model assessment insulin resistance index (HOMA-IR), and HbA 1c were measured in all participants. Genotyping analysis was performed by Mass Array Sequenom iPlex platform. Our results demonstrated that rs7578326 and rs4675095 variants were associated with increased FG levels. The rs7578326 was also associated with higher FI, HOMA-IR (B = 0.08, 95% CI [0.01, 0.15], p add = 0.025; B = 0.079, 95% CI [0.006, 0.150], p add = 0.033, respectively) in T2D, and with HbA 1c (B = 0.034, 95% CI [0.003, 0.065], p dom = 0.035) in non-drug-treated T2D. In contrast, rs2943641 C allele was associated with lower FG levels in control subjects (B = -0.17, 95% CI [-0.03, -0.002], p add = 0.030) and HbA 1c (B = 0.03, 95% CI [0.002, 0.06], p dom = 0.040) in non-drug-treated T2D. We report the association between common variants in IRS1 gene with insulin resistance, glucose, and HbA 1c levels in Bosnia and Herzegovina's population